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Abstract
© 2017 Umakhanova, Bardakov, Mavlikeev, Chernova, Magomedova, Akhmedova, Yakovlev,
Dalgatov, Fedotov, Isaev and Deev. To date, over 30 genes with mutations causing limb-girdle
muscle dystrophy have been described. Dysferlinopathies are a form of limb-girdle muscle
dystrophy type 2B with an incidence ranging from 1:1,300 to 1:200,000 in different populations.
In 1996, Dr. S. N. Illarioshkin described a family from the Botlikhsky district of Dagestan, where
limb-girdle muscle dystrophy type 2B and Miyoshi myopathy were diagnosed in 12 members
from three generations of a large Avar family. In 2000, a previously undescribed mutation in the
DYSF gene (c.TG573/574AT; p. Val67Asp) was detected in the affected members of this family.
Twenty years later, in this work, we re-examine five known and seven newly affected family
members previously diagnosed with dysferlinopathy. We observed disease progression in family
members  who were  previously  diagnosed and noted obvious  clinical  polymorphism of  the
disease. A typical clinical case is provided.
http://dx.doi.org/10.3389/fneur.2017.00077
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